Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
J Urol. 2010 Nov;184(5):1958-62. doi: 10.1016/j.juro.2010.06.137. Epub 2010 Sep 17.
The risk of under diagnosed or development of subsequent prostate cancer and the treatment of patients diagnosed with high grade prostatic intraepithelial neoplasia remain controversial. We evaluated the relationship between high grade prostatic intraepithelial neoplasia on initial biopsy and the future presence of prostate cancer.
From December 1997 to February 2008 a total of 328 men underwent a second prostate biopsy after being initially diagnosed with high grade prostatic intraepithelial neoplasia. Men with prostate cancer or atypia on initial biopsy were excluded from study. Another 335 men without high grade prostatic intraepithelial neoplasia, prostate cancer or atypia underwent a second prostate biopsy based on clinical suspicion alone. A Cox proportional hazards model was used to estimate the effect of high grade prostatic intraepithelial neoplasia on the subsequent diagnosis of prostate cancer after adjustment for prostate specific antigen, age, presence of inflammation, abnormal digital rectal examination and number of cores obtained at biopsy. High grade prostatic intraepithelial neoplasia was also stratified into multifocal disease and laterality. Adjusted Kaplan-Meier plots were generated to estimate the rates of prostate cancer.
High grade prostatic intraepithelial neoplasia alone on initial prostate biopsy had a significant effect on the subsequent diagnosis of prostate cancer (HR 1.89; 95% CI 1.39, 2.55; p <0.0001). Stratifying high grade prostatic intraepithelial neoplasia into multifocal and bilateral disease significantly increased the hazard ratios to 2.56 (95% CI 1.83, 3.60) and 2.20 (95% CI 1.51, 3.21), respectively, resulting in estimated 3-year cancer rates of 29.0% and 37.0% compared to 12.5% and 18.9%, respectively, following benign biopsy.
Multifocal and bilateral disease are adverse features of high grade prostatic intraepithelial neoplasia that significantly increase the risk of prostate cancer despite adjusting for other clinical indicators such as prostate specific antigen and abnormal digital rectal examination.
高等级前列腺上皮内瘤变(HGPI)患者存在诊断不足或发展为后续前列腺癌的风险,以及针对此类患者的治疗策略仍存在争议。本研究旨在评估初次活检中诊断为 HGPI 与未来前列腺癌发生之间的关系。
本研究纳入了自 1997 年 12 月至 2008 年 2 月期间初次诊断为 HGPI 后再次接受前列腺活检的 328 例患者。研究排除了初次活检时已诊断为前列腺癌或非典型增生的患者。另外,基于临床指征,对 335 例无 HGPI、前列腺癌或非典型增生的患者进行了第二次前列腺活检。采用 Cox 比例风险模型,在调整前列腺特异性抗原(PSA)、年龄、炎症、直肠指检异常和活检获得的核心数等因素后,评估 HGPI 对 PSA 调整后前列腺癌诊断的影响。同时,还将 HGPI 分为多灶性疾病和单侧性疾病进行分层分析。绘制调整后的 Kaplan-Meier 曲线以评估前列腺癌的发生率。
初次前列腺活检中仅诊断为 HGPI 即显著增加了前列腺癌的诊断风险(HR 1.89;95%CI 1.39,2.55;p<0.0001)。将 HGPI 进一步分层为多灶性和单侧性疾病后,其危险比显著增加至 2.56(95%CI 1.83,3.60)和 2.20(95%CI 1.51,3.21),由此导致多灶性和单侧性疾病组在经过良性活检后的 3 年癌症发生率分别为 29.0%和 37.0%,而无 HGPI 组的相应癌症发生率分别为 12.5%和 18.9%。
多灶性和单侧性疾病是 HGPI 的不良特征,即使在调整了 PSA 和直肠指检异常等其他临床指标后,它们也会显著增加前列腺癌的风险。